Biotech Startup M&A Is Reliably Delivering Some Big Exits
• Over past two years, biotech M&A exceeded $38B, surpassing many historic tech exits. • 2026 kickoff: Eli Lilly to pay up to $2.4B for Orna Therapeutics, boosting in‑vivo cell the
• Over past two years, biotech M&A exceeded $38B, surpassing many historic tech exits. • 2026 kickoff: Eli Lilly to pay up to $2.4B for Orna Therapeutics, boosting in‑vivo cell the
• 31 new unicorns joined Crunchbase board in January, highest monthly count since June 2022. • Combined $9.3B funding and $58.5B valuation added across these startups. • Four of th
• VC firms target low-margin, routine sectors like accounting and property management for AI-driven efficiency. • AI promises automation, cost cuts, and new revenue streams in trad
• Fragmented U.S. healthcare hinders provider collaboration and patient data access. • Data silos cause care gaps, delays, and higher costs for patients. • Regulatory reform and VC